A5042703700- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Rheumatoid Arthritis Research and Therapies
- COVID-19 Clinical Research Studies
- Peptidase Inhibition and Analysis
- Autoimmune and Inflammatory Disorders Research
- Lymphoma Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Retinoids in leukemia and cellular processes
- SARS-CoV-2 and COVID-19 Research
- CAR-T cell therapy research
- Heterotopic Ossification and Related Conditions
- Cancer-related Molecular Pathways
- Long-Term Effects of COVID-19
- Protein Kinase Regulation and GTPase Signaling
- Biochemical and Molecular Research
- Cancer-related gene regulation
- Cancer Treatment and Pharmacology
- Sepsis Diagnosis and Treatment
- Spondyloarthritis Studies and Treatments
- RNA Research and Splicing
Regeneron (United States)
2014-2024
Mental Health Association of Westchester County
2024
The University of Texas MD Anderson Cancer Center
2023
Roche (Switzerland)
2023
Icahn School of Medicine at Mount Sinai
2023
Scripps Research Institute
2003-2011
University of California, San Diego
2008-2011
Dana-Farber Cancer Institute
2004
Oncovir (United States)
2003
Northwestern University
2001-2003
8006 Background: Linvoseltamab is a BCMA×CD3 bispecific antibody with encouraging efficacy and manageable safety profile in patients (pts) relapsed/refractory multiple myeloma (RRMM) (Bumma et al. ASH 2022). Two Phase (Ph) 2 full dose cohorts (50 mg 200 mg) the LINKER-MM1 (NCT03761108) trial were studied to optimize selection. Methods: Ph enrolled adults MM who progressed on/after ≥3 lines of therapy (LoT) including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 (Ab),...
PURPOSE We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg 200 doses linvoseltamab, B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM). METHODS Phase II eligible patients had RRMM that either progressed on/after ≥three lines therapy including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 or was triple-class (PI/IMiD/anti-CD38) refractory. treatment once week through 14 then every 2...
Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo 24) period 1 (28 weeks), followed open-label weeks; n 43). The primary end points safety for 1, activity size of HO lesions. All experienced at least one treatment-emergent adverse event during notably...
Normal blood-cell differentiation is controlled by regulated gene expression and signal transduction. Transcription deregulation due to chromosomal translocation a common theme in hematopoietic neoplasms. AML1-ETO, which fusion protein generated the 8;21 that commonly associated with development of acute myeloid leukemia, fuses AML1 runx family DNA-binding transcription factor ETO corepressor associates histone deacetylase complexes. Analyses have demonstrated AML1-ETO blocks function...
Open-label platform trials and a prospective meta-analysis suggest efficacy of anti-interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (COVID-19) receiving corticosteroids. This study evaluated the safety sarilumab, an anti-IL-6R monoclonal antibody, treatment COVID-19.
Objective The development of biomarkers to guide treatment decisions is a major research focus in rheumatoid arthritis ( RA ). Patients with have elevated interleukin‐6 IL ‐6) levels; however, the utility ‐6 as predictor response unclear. This study was undertaken investigate, by post hoc analysis, whether baseline levels are predictive sarilumab responses 2 phase III studies. Methods Serum concentrations were measured patients prior receiving 200 mg (n = 148) or adalimumab 40 152) every...
Interleukin 6 (IL-6) signaling plays a key role in the pathophysiology of rheumatoid arthritis (RA) and is inhibited by sarilumab, human monoclonal antibody blocking IL-6 receptor alpha (IL-6Rα). The effects sarilumab plus methotrexate (MTX) on serum biomarkers joint damage bone resorption were assessed two independent studies (phase II (part A) phase III B)) patients with RA history inadequate response to MTX from MOBILITY study (NCT01061736). Serum samples analyzed at baseline prespecified...
Immunoglobulin E (IgE) is a key driver of type 1 hypersensitivity reactions and allergic disorders, which are globally increasing in number severity. Although eliminating pathogenic IgE may be powerful way to treat allergy, no therapeutic strategy reported date can fully ablate production. Interleukin-4 receptor α (IL-4Rα) signaling required for class switching, IL-4Rα blockade gradually reduces, but does not eliminate, IgE. The persistence after due long-lived + plasma cells that maintain...
Abstract Background We report pivotal results from the registrational filing data cut-off (DCO) of 200 mg dose used in LINKER-MM1 (NCT03761108) clinical trial, testing safety and efficacy linvoseltamab (a B-cell maturation antigen × CD3 antibody [Ab]) as treatment for relapsed/refractory multiple myeloma (RRMM). Methods Eligible patients had RRMM that either progressed on/after ≥3 lines therapy included a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 Ab or was...
Interleukin-6 (IL-6) is a pleiotropic cytokine that plays key role in the pathogenesis of rheumatoid arthritis. Sarilumab human monoclonal antibody binds membrane-bound and soluble IL-6 receptor-α to inhibit signalling. The aim this study was compare effects sarilumab adalimumab (a tumour necrosis factor alpha inhibitor) monotherapy on levels circulating biomarkers associated with acute-phase response, bone remodelling, atherothrombosis, anaemia chronic disease markers purported reflect...
Abstract Background Elucidating the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and clinical outcomes is critical for understanding disease 2019 (COVID-19). Methods The SARS-CoV-2 levels were analyzed by quantitative real-time polymerase chain reaction (RT-qPCR) of nasopharyngeal or oropharyngeal swab specimens collected at baseline, recorded over 60 days from 1362 COVID-19 hospitalized patients enrolled in a multicenter, randomized,...
The family of cyclin D proteins plays a crucial role in the early events mammalian cell cycle.Recent studies have revealed involvement AML1 transactivation activity promoting cycle progression through induction proteins.This information combination with our previous observation that region between amino acids 213 and 289 is important for its function led us to investigate prospective associating this region.We identified D3 by yeast two-hybrid screen detected interaction both vitro pull-down...
AML1-ETO is generated from t(8;21)(q22;q22), which a common form of chromosomal translocation associated with development acute myeloid leukemia (AML). Although full-length alone fails to promote because its detrimental effects on cell proliferation, an alternatively spliced isoform, AML1-ETO9a, without C-terminal NHR3/NHR4 domains, strongly induces leukemia. However, major fusion product in many t(8;21) AML patients, suggesting additional molecular mechanisms t(8;21)-related leukemogenesis....
Abstract Engagement of cell surface receptor tyrosine kinases by insulin and growth factors activates phosphatidylinositol 3-kinase (PI3K) generates the second messenger, 3,4,5-trisphosphate. This messenger leads to recruitment 3-phosphoinositide–dependent protein kinase-1 (PDK1) proximal side plasma membrane, which results in activation AKT kinase. In addition, PDK1 can phosphorylate numerous other kinases, including p90RSK, a kinase downstream mitogen-activated (MAPK) that is important for...
Introduction Interleukin-6 (IL-6) orchestrates formation of an inflammatory pannus, leading to joint damage in rheumatoid arthritis (RA). Sarilumab is a human monoclonal antibody blocking the IL-6Rα. In TARGET ( NCT01709578 ), phase 3 study adults with moderate-to-severe RA and inadequate response or intolerance tumour necrosis factor inhibitors, subcutaneous sarilumab 200 mg 150 every 2 weeks (q2w) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) significantly...